Learn the effects of inflammasome inhibition on body weight and fasting blood glucose in the obesity-associated cardiomyopathy animal model: https://bit.ly/3FEMQGf
ZyVersa Therapeutics Inc.
制药业
Weston，FL 942 位关注者
Restoring Health, Transforming Lives Through Innovation
关于我们
ZyVersa (Nasdaq: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging two licensed proprietary product platforms to develop pharmaceutical products that address unmet medical needs in the areas of renal and inflammatory diseases. Lead renal candidate, Phase 2a-ready VAR 200, mediates removal of excess intracellular lipids in the kidney’s filtration system that contribute to kidney damage leading to end-stage kidney disease. Lead anti-inflammatory drug candidate, inflammasome ASC inhibitor (IC 100), blocks initiation and perpetuation of damaging inflammation that’s pathogenic in a multitude of inflammatory diseases.
- 网站
-
http://www.zyversa.com
ZyVersa Therapeutics Inc.的外部链接
- 所属行业
- 制药业
- 规模
- 11-50 人
- 总部
- Weston，FL
- 类型
- 私人持股
- 创立
- 2014
- 领域
- Drug Development、Orphan Disease、Nephrology和Immunology
地点
ZyVersa Therapeutics Inc.员工
-
Peter Wolfe
CFO Director Financial Planning and Analysis with P&L Management Expertise | Open to New Opportunities
-
Greg Freitag
Board Member: PDS Biotechnology Company (NASDAQ: PDSB) and ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA)
-
Karen Cashmere
Chief Commercial Officer at ZyVersa Therapeutics Inc.
-
Steve Glover
Co-Founder, Chairman, Chief Executive Officer at ZyVersa Therapeutics
动态
-
Learn what our CEO said about the importance of inhibiting multiple inflammasome pathways with IC 100 in cardiovascular diseases: https://bit.ly/3FEMQGf
-
-
Inflammasome inhibition attenuated inflammation, heart muscle enlargement and fibrosis, and improved heart function in obesity-related cardiomyopathy. See the supportive data: https://bit.ly/3FEMQGf
-
Inflammasome inhibition reduces inflammation. Learn about its additional role in affecting metabolic activity in Alzheimer’s disease: https://bit.ly/4bMzpjr
-
Learn what our CEO said about data assessing the potential of Inflammasome ASC Inhibitor IC 100 in Parkinson’s disease: https://bit.ly/4bMzpjr
-
-
Inflammasome inhibition reduces neuroinflammation and brain deposition of amyloid beta contributing to Alzheimer’s disease progression. Learn how: https://bit.ly/4bMzpjr
-
Learn about the metabolic improvements seen with inflammasome inhibition: http://bit.ly/41FrfWL
-
Learn what our CEO said about how the data supports selection of IC 100’s lead indication, obesity with metabolic complications: http://bit.ly/41FrfWL
-
-
Cardio protection & improved metabolism with inflammasome inhibition correlated with reduced inflammation and macrophage activation in cardiac and adipose tissue. Learn more: http://bit.ly/41FrfWL
-
Attending JPM in San Francisco January 13 - 16, 2025? Learn about ZyVersa’s near-term milestones for Inflammasome Inhibitor IC 100 and Renal Cholesterol Efflux Mediator™ VAR 200 https://bit.ly/4fo5o9U
-